MQS Management LLC Makes New $383,000 Investment in Hologic, Inc. (NASDAQ:HOLX)

MQS Management LLC bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,155 shares of the medical equipment provider’s stock, valued at approximately $383,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Massmutual Trust Co. FSB ADV boosted its holdings in Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares in the last quarter. Graypoint LLC raised its stake in shares of Hologic by 3.9% during the 1st quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock worth $302,000 after buying an additional 147 shares during the last quarter. Sequoia Financial Advisors LLC grew its stake in Hologic by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after acquiring an additional 165 shares during the last quarter. Parallel Advisors LLC increased its holdings in Hologic by 11.5% during the 4th quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock valued at $131,000 after acquiring an additional 189 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Hologic by 0.6% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 31,112 shares of the medical equipment provider’s stock valued at $2,425,000 after purchasing an additional 192 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

HOLX stock opened at $82.40 on Friday. The stock’s 50 day moving average is $80.63 and its two-hundred day moving average is $77.01. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $84.67. The company has a market capitalization of $19.23 billion, a PE ratio of 42.04, a P/E/G ratio of 2.53 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the firm earned $0.93 earnings per share. The business’s revenue was up 2.7% compared to the same quarter last year. Analysts predict that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now directly owns 45,472 shares in the company, valued at $3,615,024. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now owns 45,472 shares in the company, valued at $3,615,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

HOLX has been the topic of several recent research reports. Evercore ISI upped their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Tuesday. JPMorgan Chase & Co. increased their target price on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Finally, Stephens restated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.60.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.